The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
